CJC-1295 (without DAC / Mod GRF 1-29) vs GHRP-6

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

✅ Stacking Partners — These compounds are commonly used together and may have synergistic effects.
CJC-1295 (without DAC / Mod GRF 1-29)GHRP-6
CategoryPeptidesPeptides
Standard DoseResearch indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.
TimingBest administered at bedtime (primary), upon waking, and/or post-workout. Always on empty stomach — wait 2+ hours after last meal. Avoid carbohydrates 30+ minutes after injection.On empty stomach, 30+ minutes before meals. Bedtime dose most important. The strong hunger effect makes pre-meal timing practical.
Cycle Duration12-24 week cycles with 4-8 week breaks.8-16 week cycles.
Evidence Levelmoderate_humanmoderate_human

Mechanism

Mod GRF 1-29 (Modified Growth Hormone Releasing Factor, amino acids 1-29) is a truncated and modified GHRH analog that binds to GHRH receptors on anterior pituitary somatotrophs, activating cAMP via Gs protein/adenylate cyclase and mitogen-activated protein kinase pathways. Without the DAC moiety, it has a short half-life of approximately 30 minutes, producing acute GH pulses that more closely mimic natural pulsatile GH secretion. It also stimulates pituitary gene transcription of GH mRNA, preserving endogenous pituitary reserve.

Standard Dosing

Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.

Timing

Best administered at bedtime (primary), upon waking, and/or post-workout. Always on empty stomach — wait 2+ hours after last meal. Avoid carbohydrates 30+ minutes after injection.

Cycle Duration

12-24 week cycles with 4-8 week breaks.

Side Effects

  • Flushing post-injection
  • Head rush
  • Hunger increase
  • Water retention (mild)
  • Tingling in extremities

Contraindications

  • Active cancer
  • Diabetic retinopathy
  • Pregnancy and breastfeeding
  • Intracranial hypertension

Best Stacking Partners

IpamorelinGHRP-2GHRP-6Hexarelin
B

GHRP-6

Peptides

Mechanism

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates GH release through activation of the growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor) on pituitary somatotrophs. It acts via dual sites — pituitary and hypothalamic — possibly involving regulatory factors beyond GHRH and somatostatin. GHRP-6 also stimulates ghrelin-mediated appetite signaling, increases cortisol and prolactin release, and has demonstrated cytoprotective properties including cardioprotection.

Standard Dosing

Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.

Timing

On empty stomach, 30+ minutes before meals. Bedtime dose most important. The strong hunger effect makes pre-meal timing practical.

Cycle Duration

8-16 week cycles.

Side Effects

  • Intense hunger (primary distinguishing side effect)
  • Water retention
  • Cortisol elevation
  • Prolactin elevation
  • Tingling and numbness
  • Injection site pain

Contraindications

  • Active cancer
  • Obesity (significant appetite stimulation)
  • Cushing's syndrome
  • Pregnancy and breastfeeding

Best Stacking Partners

CJC-1295 (no DAC)Sermorelin

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →